These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 200569)

  • 1. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy.
    Henle W; Ho JH; Henle G; Chau JC; Kwan HC
    Int J Cancer; 1977 Nov; 20(5):663-72. PubMed ID: 200569
    [No Abstract]   [Full Text] [Related]  

  • 2. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 3. Epstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinoma.
    Neel HB; Taylor WF
    Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1287-90. PubMed ID: 2173618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of serologic test for EB-virus antibody in occult type nasopharyngeal carcinoma.
    Furukawa M; Takimoto T; Morishita K; Komori T; Ishiguro H; Umeda R
    Auris Nasus Larynx; 1983; 10(1):43-8. PubMed ID: 6311149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Epstein Barr virus antibody in nasopharyngeal carcinoma.
    Hsu MM; Chiou JF; McCabe BF
    Ann Otol Rhinol Laryngol; 1974; 83(1):19-25. PubMed ID: 4359674
    [No Abstract]   [Full Text] [Related]  

  • 6. The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology.
    Falser N
    Arch Otorhinolaryngol; 1984; 239(1):15-23. PubMed ID: 6318710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rhinopharyngeal carcinoma and Epstein-Barr virus: study of a sample of Italian patients].
    Caliceti U; Cevenini R; Donati M
    Acta Otorhinolaryngol Ital; 1985; 5(1):83-90. PubMed ID: 2994355
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-EBV serologic tests for nasopharyngeal carcinoma.
    Neel HB; Pearson GR; Weiland LH; Taylor WF; Goepfert HH; Pilch BZ; Lanier AP; Huang AT; Hyams VJ; Levine PH; Henle G; Henle W
    Laryngoscope; 1980 Dec; 90(12):1981-90. PubMed ID: 6256597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.
    Desgranges C; de-The G
    IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
    [No Abstract]   [Full Text] [Related]  

  • 12. [125I] Clq-binding activity and its relationship with anti-Epstein--Barr virus antibodies in sera from nasopharyngeal carcinoma patients.
    Lamelin JP; Vincent C; Souissi T; Revillard JP
    Eur J Cancer (1965); 1979 Feb; 15(2):163-71. PubMed ID: 220051
    [No Abstract]   [Full Text] [Related]  

  • 13. Epstein-Barr virus specific antibodies in patients with IgA nephropathy.
    Wu AY; Lau YK; Chia KB; Lim CH
    Singapore Med J; 1988 Jun; 29(3):257-60. PubMed ID: 2847323
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
    Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
    Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma.
    Lynn TC; Tu SM; Kawamura A
    J Laryngol Otol; 1985 Jun; 99(6):567-72. PubMed ID: 2989398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis.
    Naegele RF; Champion J; Murphy S; Henle G; Henle W
    Int J Cancer; 1982 Feb; 29(2):209-12. PubMed ID: 6174465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals.
    Zhu XX; Zeng Y; Wolf H
    Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein--Barr virus-associated antibodies in IgG and IgA of nasopharyngeal carcinoma patients.
    Yang CS; Yang HM; Yeh YS; Lynn TC
    Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):167-75. PubMed ID: 228890
    [No Abstract]   [Full Text] [Related]  

  • 19. Nasopharyngeal carcinoma and Burkitt's lymphoma in a Canadian family. I. HLA typing, EBV antibodies and serum immunoglobulins.
    Joncas JH; Rioux E; Wastiaux JP; Leyritz M; Robillard L; Menezes J
    Can Med Assoc J; 1976 Nov; 115(9):858-60. PubMed ID: 186168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA and nasopharyngeal carcinoma.
    Desgranges C; De-The G
    IARC Sci Publ (1971); 1978; (24 Pt 2):883-91. PubMed ID: 221410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.